Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | VP of Operations | March 25, 2019 | March 26, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date March 25, 2019 · Filed March 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2020-12-14 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-25 · Disposition to issuer · Disposed 4,000 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2020-12-14 | Direct | 4,000 |
Reported balance
After 2019-03-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-25 · Grant · Acquired 4,000 · Balance 4,000 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2021-04-20 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-25 · Disposition to issuer · Disposed 300 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1: The option is exercisable to the extent of 100 shares on each of April 21, 2011, April 21, 2012 and April 21, 2013. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2021-04-20 | Direct | 300 |
Reported balance
After 2019-03-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-25 · Grant · Acquired 300 · Balance 300 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1: The option is exercisable to the extent of 100 shares on each of April 21, 2011, April 21, 2012 and April 21, 2013. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2022-02-09 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-03-25 · Disposition to issuer · Disposed 1,500 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2: The option is exercisable to the extent of 750 shares on each of February 10, 2012 and February 10, 2013. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2022-02-09 | Direct | 1,500 |
Reported balance
After 2019-03-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-25 · Grant · Acquired 1,500 · Balance 1,500 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2: The option is exercisable to the extent of 750 shares on each of February 10, 2012 and February 10, 2013. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2022-12-07 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-03-25 · Disposition to issuer · Disposed 2,500 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3: The option is exercisable to the extent of 1,250 shares on each of December 7, 2012 and December 7, 2013. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2022-12-07 | Direct | 2,500 |
Reported balance
After 2019-03-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-03-25 · Grant · Acquired 2,500 · Balance 2,500 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3: The option is exercisable to the extent of 1,250 shares on each of December 7, 2012 and December 7, 2013. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2023-10-04 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-03-25 · Disposition to issuer · Disposed 4,000 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4: The option is exercisable to the extent of 2,000 shares on each of October 4, 2013 and October 4, 2014. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2023-10-04 | Direct | 4,000 |
Reported balance
After 2019-03-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-03-25 · Grant · Acquired 4,000 · Balance 4,000 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4: The option is exercisable to the extent of 2,000 shares on each of October 4, 2013 and October 4, 2014. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2024-02-18 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-03-25 · Disposition to issuer · Disposed 6,250 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5: The option is exercisable to the extent of 2,084 shares on February 18, 2014, and 2,083 shares on each of February 18, 2015 and February 18, 2016. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2024-02-18 | Direct | 6,250 |
Reported balance
After 2019-03-25 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-03-25 · Grant · Acquired 6,250 · Balance 6,250 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5: The option is exercisable to the extent of 2,084 shares on February 18, 2014, and 2,083 shares on each of February 18, 2015 and February 18, 2016. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2024-10-23 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-03-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6: The option is exercisable to the extent of 3,334 shares on October 23, 2015 and 3,333 shares on each of October 23, 2016 and October 23, 2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2024-10-23 | Direct | 10,000 |
Reported balance
After 2019-03-25 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-03-25 · Grant · Acquired 10,000 · Balance 10,000 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6: The option is exercisable to the extent of 3,334 shares on October 23, 2015 and 3,333 shares on each of October 23, 2016 and October 23, 2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2025-09-04 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-03-25 · Disposition to issuer · Disposed 25,500 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7: The option is exercisable to the extent of 8,500 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2025-09-04 | Direct | 25,500 |
Reported balance
After 2019-03-25 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2019-03-25 · Grant · Acquired 25,500 · Balance 25,500 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7: The option is exercisable to the extent of 8,500 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2019-03-25 · Disposition to issuer · Disposed 40,000 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8: The option is exercisable to the extent of 13,334 shares on June 10, 2017 and 13,333 shares on each of June 10, 2018 and June 10, 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2026-06-10 | Direct | 40,000 |
Reported balance
After 2019-03-25 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2019-03-25 · Grant · Acquired 40,000 · Balance 40,000 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8: The option is exercisable to the extent of 13,334 shares on June 10, 2017 and 13,333 shares on each of June 10, 2018 and June 10, 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2027-07-12 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2019-03-25 · Disposition to issuer · Disposed 30,000 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F9: The option is exercisable to the extent of 10,000 shares on each of July 12, 2018, July 12, 2019 and July 12, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2027-07-12 | Direct | 30,000 |
Reported balance
After 2019-03-25 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2019-03-25 · Grant · Acquired 30,000 · Balance 30,000 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F9: The option is exercisable to the extent of 10,000 shares on each of July 12, 2018, July 12, 2019 and July 12, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2027-08-10 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2019-03-25 · Disposition to issuer · Disposed 20,000 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F10: The option is exercisable to the extent of 6,667 shares on each of August 10, 2018 and August 10, 2019, and 6,666 shares on August 10, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2027-08-10 | Direct | 20,000 |
Reported balance
After 2019-03-25 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2019-03-25 · Grant · Acquired 20,000 · Balance 20,000 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F10: The option is exercisable to the extent of 6,667 shares on each of August 10, 2018 and August 10, 2019, and 6,666 shares on August 10, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2028-10-29 | Direct | 0 |
Reported balance
After 2019-03-25 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2019-03-25 · Disposition to issuer · Disposed 50,000 · Balance 0 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F11: The option is exercisable to the extent of 16,667 shares on each of October 29, 2019 and October 29, 2020, and 16,666 shares on October 29, 2021. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2028-10-29 | Direct | 50,000 |
Reported balance
After 2019-03-25 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2019-03-25 · Grant · Acquired 50,000 · Balance 50,000 F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F11: The option is exercisable to the extent of 16,667 shares on each of October 29, 2019 and October 29, 2020, and 16,666 shares on October 29, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is exercisable to the extent of 100 shares on each of April 21, 2011, April 21, 2012 and April 21, 2013.
F2: The option is exercisable to the extent of 750 shares on each of February 10, 2012 and February 10, 2013.
F3: The option is exercisable to the extent of 1,250 shares on each of December 7, 2012 and December 7, 2013.
F4: The option is exercisable to the extent of 2,000 shares on each of October 4, 2013 and October 4, 2014.
F5: The option is exercisable to the extent of 2,084 shares on February 18, 2014, and 2,083 shares on each of February 18, 2015 and February 18, 2016.
F6: The option is exercisable to the extent of 3,334 shares on October 23, 2015 and 3,333 shares on each of October 23, 2016 and October 23, 2017.
F7: The option is exercisable to the extent of 8,500 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018.
F8: The option is exercisable to the extent of 13,334 shares on June 10, 2017 and 13,333 shares on each of June 10, 2018 and June 10, 2019.
F9: The option is exercisable to the extent of 10,000 shares on each of July 12, 2018, July 12, 2019 and July 12, 2020.
F10: The option is exercisable to the extent of 6,667 shares on each of August 10, 2018 and August 10, 2019, and 6,666 shares on August 10, 2020.
F11: The option is exercisable to the extent of 16,667 shares on each of October 29, 2019 and October 29, 2020, and 16,666 shares on October 29, 2021.
F12: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 50,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 24 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-10-29 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F11 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of October 29, 2019 and October 29, 2020, and 16,666 shares on October 29, 2021. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 50,000 | Not disclosed Strike: $1.23 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 23 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2028-10-29 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F11 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of October 29, 2019 and October 29, 2020, and 16,666 shares on October 29, 2021. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 20,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 22 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-08-10 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F10 · derivative.exercise_date: The option is exercisable to the extent of 6,667 shares on each of August 10, 2018 and August 10, 2019, and 6,666 shares on August 10, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 20,000 | Not disclosed Strike: $3.35 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 21 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-08-10 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F10 · derivative.exercise_date: The option is exercisable to the extent of 6,667 shares on each of August 10, 2018 and August 10, 2019, and 6,666 shares on August 10, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 30,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 20 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-07-12 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F9 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on each of July 12, 2018, July 12, 2019 and July 12, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 30,000 | Not disclosed Strike: $2.80 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 19 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-07-12 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F9 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on each of July 12, 2018, July 12, 2019 and July 12, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 40,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 18 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2026-06-10 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8 · derivative.exercise_date: The option is exercisable to the extent of 13,334 shares on June 10, 2017 and 13,333 shares on each of June 10, 2018 and June 10, 2019. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 40,000 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 17 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2026-06-10 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8 · derivative.exercise_date: The option is exercisable to the extent of 13,334 shares on June 10, 2017 and 13,333 shares on each of June 10, 2018 and June 10, 2019. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 25,500 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 16 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2025-09-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 8,500 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 25,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 15 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,500 shares Expires 2025-09-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 8,500 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 10,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 14 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2024-10-23 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 3,334 shares on October 23, 2015 and 3,333 shares on each of October 23, 2016 and October 23, 2017. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 10,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 13 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-10-23 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 3,334 shares on October 23, 2015 and 3,333 shares on each of October 23, 2016 and October 23, 2017. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 6,250 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 12 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2024-02-18 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 2,084 shares on February 18, 2014, and 2,083 shares on each of February 18, 2015 and February 18, 2016. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 6,250 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 11 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2024-02-18 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 2,084 shares on February 18, 2014, and 2,083 shares on each of February 18, 2015 and February 18, 2016. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 10 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2023-10-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 9 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2023-10-04 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 2,500 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 8 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2022-12-07 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 1,250 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 2,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 7 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2022-12-07 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 1,250 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 1,500 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 6 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2022-02-09 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 750 shares on each of February 10, 2012 and February 10, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 1,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 5 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2022-02-09 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 750 shares on each of February 10, 2012 and February 10, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 300 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 4 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires 2021-04-20 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 100 shares on each of April 21, 2011, April 21, 2012 and April 21, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 300 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 3 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2021-04-20 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 100 shares on each of April 21, 2011, April 21, 2012 and April 21, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 2 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2020-12-14 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007658 · doc1.xml · derivative · entry 1 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-12-14 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 20:00 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001567619-18-004859 · doc1.xml · derivative · entry 12 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-10-29 F11 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of October 29, 2019 and October 29, 2020, and 16,666 shares on October 29, 2021. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 18:19 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-17-031342 · doc1.xml · derivative · entry 11 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-08-10 F10 · derivative.exercise_date: The option is exercisable to the extent of 6,667 shares on each of August 10, 2018 and August 10, 2019, and 6,666 shares on August 10, 2020. Read SEC document |
| July 12, 2017 Filed Jul 13, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001140361-17-027822 · doc1.xml · derivative · entry 10 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-07-12 F9 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on each of July 12, 2018, July 12, 2019 and July 12, 2020. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 25,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 16 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2025-09-04 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 8,500 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 25,500 | Not disclosed Strike: $7.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 15 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,500 shares Expires 2025-09-04 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 8,500 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 10,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 14 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2024-10-23 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 3,334 shares on October 23, 2015 and 3,333 shares on each of October 23, 2016 and October 23, 2017. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 10,000 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 13 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-10-23 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 3,334 shares on October 23, 2015 and 3,333 shares on each of October 23, 2016 and October 23, 2017. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 6,250 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 12 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2024-02-18 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 2,084 shares on February 18, 2014, and 2,083 shares on each of February 18, 2015 and February 18, 2016. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 6,250 | Not disclosed Strike: $13.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 11 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2024-02-18 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 2,084 shares on February 18, 2014, and 2,083 shares on each of February 18, 2015 and February 18, 2016. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 10 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2023-10-04 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $12.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 9 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2023-10-04 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 2,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 8 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2022-12-07 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 1,250 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 2,500 | Not disclosed Strike: $30.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 7 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2022-12-07 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 1,250 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 1,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 6 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2022-02-09 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 750 shares on each of February 10, 2012 and February 10, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 1,500 | Not disclosed Strike: $21.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 5 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2022-02-09 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 750 shares on each of February 10, 2012 and February 10, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 300 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 4 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires 2021-04-20 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 100 shares on each of April 21, 2011, April 21, 2012 and April 21, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 300 | Not disclosed Strike: $20.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 3 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2021-04-20 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 100 shares on each of April 21, 2011, April 21, 2012 and April 21, 2013. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 2 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2020-12-14 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:48 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007738 · doc1.xml · derivative · entry 1 Clyde Mandy D. · CIK 0001527239 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-12-14 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.